A single-dose study of denosumab in patients with various degrees of renal impairment.
about
A review of denosumab for the treatment of osteoporosisDenosumab for the treatment of osteoporosisNew antiresorptive therapies for postmenopausal osteoporosisDiagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation OncologyBone-targeted therapy in metastatic breast cancer - all well-established knowledge?Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate CancerChronic kidney disease and osteoporosis: evaluation and management.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancerSide effects of bone-targeted therapies in advanced breast cancer.Treatment of immobilization-related hypercalcaemia with denosumab.Prolonged hypocalcaemia following a single dose of 60 mg denosumab in two patients with CKD 4/5 on cinacalcet treatment for tertiary hyperparathyroidism.Chronic kidney disease and the skeleton.Management of severe osteoporosis.Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerSpecific method validation and sample analysis approaches for biocomparability studies of denosumab addressing method and manufacture site changesToxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.Bisphosphonates for Osteoporosis in Patients with Renal Insufficiency: Pharmacists' Practices and Beliefs.Impact of denosumab on bone mass in cancer patients.Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease.Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab.High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.The Strategy to Prevent and Regress the Vascular Calcification in Dialysis Patients.Osteoporosis in men: epidemiology and treatment with denosumab.Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions.Therapy for patients with CKD and low bone mineral density.Denosumab in osteoporosis.The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.Managing bone metastases and reducing skeletal related events in prostate cancer.Biological agents in management of osteoporosis.Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.Considerations regarding adherence of anti-osteoporosis therapy.Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.How to predict and treat increased fracture risk in chronic kidney disease.Clinical efficacy of denosumab versus bisphosphonates for the prevention of bone complications: implications for nursing.Bone Disorders in Chronic Kidney Disease: An Update in Diagnosis and Management.Denosumab: an Emerging Therapy in Pediatric Bone Disorders.The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.Osteoprotegerin and uremic osteoporosis in chronic hemodialysis patients.Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density.
P2860
Q27005894-54047400-DAF3-4058-8AB2-B5A594872683Q27009275-5E9CBA05-8A34-45D3-8480-C7BAA88165E6Q27014775-24F51356-F512-4506-8CF3-14E760B2A32AQ28076646-B4DCB2BF-E61E-49D8-86A7-4E8C9A831555Q28087676-7DA14EB4-97E4-4C56-9ADB-FB28F0BC049FQ30234751-C65A16E1-F959-4C90-A091-922B73E1F84BQ33611876-75600CC4-80FE-42F6-9770-F1CAE1FEF3B0Q33833414-002C240E-47F9-44F4-A202-186BD5726B21Q34023510-793A8BF6-D4D6-4C21-A4E1-AA5CDB701DF8Q35066955-690E86C3-A406-4157-9DB8-C3D7B64594C0Q35453039-E2A214CC-73C8-4113-9248-DD51BE8EDB6EQ35608481-D1A1E7DE-C8A1-4E4B-967F-1BFEC7463DD1Q35755179-BD5B23D4-49EF-44BD-9300-47224F308279Q35852252-A7A13D27-8C1F-43C8-A040-5DEE04A9DEE2Q36345986-6EEE196D-7ED5-4D61-A515-47E09AC054F9Q36502429-2B10E49A-CE32-4155-B80E-265621666465Q36553506-769E45EA-E346-42C7-9312-133243F381C4Q36649495-CD9B5B96-DF29-42CD-A8AD-B5FC3F5F966BQ37000157-BEC2E5FF-1545-48BE-B092-2D1E2CE5A741Q37327059-62D41111-B438-4A14-AF6B-4C0309F040A9Q37443111-55D23FCB-4892-4114-AB74-576DB1218695Q37488814-0512EADE-7A2D-4EFB-9395-59131204EA2CQ37670856-37818E16-FAB6-486B-8770-C3FE659DA933Q37702188-F6891ABF-BEB4-482C-92A2-5440967B6FE6Q38144897-F6C61CB0-6457-4F93-9C81-783F7425324CQ38150099-C000FC26-96D6-4F03-AE01-EFA333115E1FQ38167352-1C60ED5C-83B4-4088-AF29-48DC5990852CQ38193181-702EB417-32F5-4D67-BADE-25E8DB64C2B1Q38211359-4B446257-9571-41CF-99E3-4824CD175A6CQ38247465-73E935DB-EE33-4901-845C-432A3EA741D5Q38271045-87246A88-62FB-4F50-A408-9A1CE2E8CCA9Q38294766-2A0EE4B2-ED27-4451-85B6-D726AF53C84EQ38364467-1CEA9CC2-B704-4C32-B0C2-091E7B3B01F9Q38372851-1CFE47FD-75B2-4113-83C7-357C4F9FD4F3Q38571774-F4FA1A0E-9CBE-4F8C-ACC0-E5B48CA4A575Q38579166-E157BEA2-16B4-4E53-A467-BE57E24AD7C7Q38712724-C84E84A3-A654-44C7-AC67-C349CA35009EQ38733725-C67FDD22-E426-49E9-9003-170037B135CEQ38978628-D52CE30C-2A30-4868-9B6F-FD927C9046AFQ38984955-42FF1892-B4E8-4285-A29E-05F8D412C0D4
P2860
A single-dose study of denosumab in patients with various degrees of renal impairment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
A single-dose study of denosumab in patients with various degrees of renal impairment.
@ast
A single-dose study of denosumab in patients with various degrees of renal impairment.
@en
type
label
A single-dose study of denosumab in patients with various degrees of renal impairment.
@ast
A single-dose study of denosumab in patients with various degrees of renal impairment.
@en
prefLabel
A single-dose study of denosumab in patients with various degrees of renal impairment.
@ast
A single-dose study of denosumab in patients with various degrees of renal impairment.
@en
P2093
P2860
P356
P1476
A single-dose study of denosumab in patients with various degrees of renal impairment.
@en
P2093
Desmond Padhi
Edward Lee
Geoffrey A Block
Henry G Bone
Liang Fang
P2860
P304
P356
10.1002/JBMR.1613
P577
2012-07-01T00:00:00Z